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Abstract
Current therapies to treat asthma and other airway diseases primarily include anti-inflammatory 
agents and bronchodilators. Anti-inflammatory agents target trafficking and resident immunocytes 
and structural cells, while bronchodilators act to prevent or reverse shortening of airway smooth 
muscle (ASM), the pivotal tissue regulating bronchomotor tone. Advances in our understanding of 
the biology of G protein-coupled receptors (GPCRs) and biased agonism offers unique 
opportunities to modulate GPCR function that include the use of pepducins and allosteric 
modulators. Recent evidence suggests that small molecule inhibitors of Gαq as well as pepducins 
targeting Gq-coupled receptors can broadly inhibit contractile agonist-induced ASM function. 
Given these advances, new therapeutic approaches can be leveraged to diminish the global rise in 
morbidity and mortality associated with asthma and chronic obstructive pulmonary disease.
Summary
Despite considerable research efforts, asthma and COPD remain substantial therapeutic challenges 
and contribute globally to increasing morbidity and mortality. Bronchodilators reverse or prevent 
shortening of airway smooth muscle, and remain principal drugs in both prophylactic management 
and treatment of obstructive airway diseases. Over the past two decades, advances in management 
of the non-severe asthma/COPD patient have been limited to modest refinements in traditional 
bronchodilator drugs. Recent advances in GPCR biology and structural protein biochemistry offer 
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unparalleled opportunities to develop novel therapeutic approaches that either activate or inhibit 
GPCR function. Coupling these discoveries to leveraging delivery systems that specifically target 
the airways may profoundly affect the morbidity and mortality in airway diseases.
Introduction
Profound advances in the fields of receptor biology and pharmacology have now identified 
novel approaches to modulate the function of G protein-coupled receptors (GPCRs), the 
largest super family of cell-surface receptors in the human genome [1,2]. Although the 
concept of rational drug design has existed for decades, only recently have structural biology 
and molecular modeling capabilities advanced this concept beyond the theoretical stage. 
Providing a further boost is the related and exploding field of biased ligand pharmacology, 
whose insights have greatly advanced our understanding of qualitative GPCR signaling. One 
intriguing discovery 16 years ago was the identification that receptor intracellular surface 
loops that interact with G proteins can be targeted by N-terminal lipidated peptides 
(pepducins) to modulate GPCR signaling and potentially serve as therapeutics [1,3].
Current therapies to treat asthma and other airway diseases primarily include anti-
inflammatory agents and bronchodilators. Anti-inflammatory agents target trafficking and 
resident immunocytes and structural cells, while bronchodilators act to prevent or reverse 
shortening of airway smooth muscle (ASM), the pivotal tissue regulating bronchomotor 
tone. Unfortunately, about 50% of patients with asthma have inadequate control with current 
therapeutics [4]. Despite some refinements in the duration and specificity of β2-adrenergic 
receptor (β2AR) agonists and in the use of antagonists of contractile GPCRs in asthma, 
continued refinement may yield diminishing returns and truly novel approaches will be 
needed to overcome current limitations and address the needs of patients not served by 
currently available therapies.
Most bronchodilators are GPCR ligands which exert their action by either promoting pro-
relaxant or inhibiting pro-contractile signaling. This underscores the importance of the 
competitive balance of pro-relaxant and pro-contractile GPCR signaling in regulating ASM 
contractility and airway resistance in obstructive lung diseases [5–7]. Airway resistance is 
also affected by structural changes in the airways (airway remodeling) and pulmonary 
architecture as well as tissue mechanics, but GPCR ligands acting on ASM have the 
strongest impact on changes in airflow.
Increased levels of endogenous contractile GPCR agonists have been associated with 
allergic airway inflammation, leading to increased ASM contraction and airflow obstruction. 
One strategy to ameliorate this is to inhibit pro-contractile GPCR signaling by administering 
a small molecule antagonist of a pro-contractile receptor. This approach may be suboptimal 
or entirely ineffective when multiple GPCRs are activated to contract ASM. Treatment with 
β-agonists relaxes airways by antagonizing pro-contractile GPCRs at several loci in airway 
smooth muscle including transmembrane receptor signaling, calcium mobilization and flux, 
and distal regulation of contractile filaments through regulation of myosin light chain kinase/ 
phosphatase (MLCK/MLCP) activity. Therefore, use of β-agonists has an inherent 
advantage over selective antagonists of pro-contractile GPCRs as β-agonists dilate/protect 
Panettieri et al. Page 2
Curr Opin Pharmacol. Author manuscript; available in PMC 2019 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
airways irrespective of the type of pro-contractile stimulus. Even though inhaled β-agonists 
are the mainstay therapy for acute bronchospasm and combined long-acting β-agonist 
(LABA) and corticosteroid treatment is the cornerstone of asthma and chronic obstructive 
pulmonary disease (COPD) maintenance therapy, concerns about β-agonist efficacy and 
safety have persisted for decades. Chronic β-agonist use has been associated with β2AR 
tachyphylaxis [8–10], loss of asthma control [11–13], and death [14–17]. Although 
associations of chronic β-agonist use with adverse events have not been uniquely observed 
in all studies [18–20], the need for understanding mechanisms involved in detrimental 
effects of β-agonists on lung physiology and pathology remains.
Fortunately, recent basic science research in GPCR biology and pharmacology has 
discovered novel modes of GPCR signaling and regulation that potentially explains the 
complex effects of existing drugs while offering the promise of new, more efficacious drugs. 
In this review, we summarize studies based on newfound paradigms in GPCR biology to (1) 
identify strategies capable of making existing asthma and COPD drugs better; and (2) 
develop new drugs that work by distinctly different mechanisms.
Diverse receptor conformations are linked to differential signaling events; 
arrestins and biased ligands can influence the qualitative nature of 
signaling
GPCR ligands are often characterized based on their efficacy, be it positive or negative, to a 
specific signaling pathway that is in turn linked to a specific cellular function. However, it 
has been apparent for some time that there exists a much greater complexity of ligand-
receptor interactions, and recent studies that attempt to explain ‘why’ are probably only 
scratching the surface of the regulatory phenomena that enable receptor dexterity. Numerous 
GPCRs exhibit significant diversity in their capacity to activate multiple signaling pathways, 
linked to either other G proteins or in a G protein-independent manner. Some ligands engage 
a receptor to induce a distinct receptor conformation capable of activating one signaling 
pathway while inhibiting another pathway. This phenomenon, referred to ‘functional 
selectivity’ or ‘biased agonism’, has been demonstrated for a number of GPCRs. The 5-
HT2CR ligand SB 242084, promoted 5-HT2cR-mediated PLC activation [21] but inhibited 5-
HT2cR-mediated activation of phospholipase A2 (PLA2) and the subsequent release of 
arachidonic acid (AA)[22]. In a somewhat striking observation, studies by Stout et al. [23] 
show that the agonist efficacy of ligands does not correlate with the capacity to induce 
desensitization of the different signaling pathways, therefore suggesting differential 
regulation of desensitization by various ligands of the 5-HT2cR. Similar observations have 
been made for 5-H2A, µ-opioid, somatostatin, and chole-cystokinin receptors, where the 
level of efficacy of various ligands is dissociated from the ability to promote agonist-induced 
receptor desensitization (reviewed in [24]). Studies of D2 [25] and D1 dopamine [26], H1 
histamine [27] and V2 vasopressin [24,28] receptors have identified ligands that exhibit 
differential abilities in pathway activation and receptor desensitization and trafficking.
Agonism bias is also exhibited towards G protein-independent signaling. Arrestins have now 
become established as the most prominent G protein-independent signaling molecules 
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(Figure 1). Arrestins were initially characterized as important regulators of receptor 
desensitization and internalization; arrestins are recruited to activated GPCRs where they 
subsequently hinder G protein recruitment and facilitate receptor internalization via clathrin-
coated pits [29]. More recently arrestins have been proposed to act as signaling scaffolds and 
a large body of evidence now supports the capacity of various ligands to promote β-arrestin-
dependent signaling events in absence of G protein activation. ICI 118,551 and propranolol, 
both inverse agonists for β2AR-mediated Gs activation, have been shown to induce β2AR-
mediated arrestin-dependent p42/p44 activation [30]. This differential efficacy has been 
observed for other receptors including the V2 vasopressin receptor [30] and the 
angiotensin-1 receptor [31]; which both have the ability to activate p42/p44 via β-arrestin 
recruitment independent of Gq activation when bound to their respective biased ligands.
Collectively, these findings demonstrate that GPCR ligands can induce a range of distinct 
receptor conformations which determine signaling outcomes. Wisler et al. [32] identified 
carvedilol as having a unique profile out of a panel of 16 βAR ligands: it is an inverse 
agonist for βAR-mediated Gs signaling but stimulates receptor phosphorylation, recruits 
beta-arrestin, promotes receptor internalization and activates p42/p44 in an arrestin-
dependent manner. The authors hypothesize that this unique profile contributes to the 
effectiveness of carvedilol in treatment of heart failure. Current evidence suggests that 
biased agonism, through either choice of orthosteric ligands, use of allosteric modulators, 
direct targeting of G proteins, or manipulation of GRK and arrestin function, can be realized 
to tailor GPCR function and improve our ability to modulate airway inflammation and/or 
promote bronchodilation.
Novel strategies co-opting heterotrimeric G protein regulatory mechanisms 
can regulate ASM contraction
GPCRs in ASM represent attractive therapeutic targets for multiple reasons, including the 
ability to readily target them with selective agents (inhaled small molecules). Approaches for 
targeting downstream elements have some conceptual appeal; for example, broad-based 
strategies for inhibiting the heterotrimeric Gq protein could be an effective means of 
negating the effects of all pro-contractile agonists in the inflamed airway, and overcoming 
the limitations of monotherapies such as tiotropium and montelukast [33]. To date, however, 
such approaches have not materialized as sufficiently selective and deliverable reagents have 
not been developed. However, recent studies have determined experimental approaches for 
manipulating heterotrimeric G protein function, many discovered as a consequence of our 
improved understanding of GPCR-G protein coupling, RGS function, and structural biology 
of heterotrimeric G proteins. We feel such approaches can be adapted to inhibit Gq 
signaling, and consequently Gq-mediated contraction, in ASM.
Multiple strategies designed to interdict GPCR-Gq or Gq-PLC coupling as a means of global 
inhibition of Gq-coupled receptor signaling may offer new therapeutic approaches in airway 
diseases. Strategies include pepducins (Figure 2) that function as broad-based antagonists of 
Gq signaling, lipidated Gαq peptides that selectively disrupt GPCR/Gq coupling, and small 
molecule inhibitors of Gbg-mediated signaling. Importantly, most of these strategies employ 
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lipidated peptides that are amenable to delivery to the airway and ASM cells, and are more 
likely to specifically engage their target than are gene delivery approaches that are often 
required for targeting protein– protein interactions.
Our initial efforts to bias signaling with lipidated peptides focused on the development of 
pepducins derived from the intracellular regions of a GPCR [1]. The Benovic laboratory 
found that pepducins from the third intracellular loop (ICL3) of the β2AR could mediate Gs-
biased signaling [34] while pepducins from ICL1 mediated arrestin-biased signaling [35]. 
Some ICL3 pepducins were found to stabilize a conformation of the β2AR that interacted 
selectively with Gs while other ICL3 pepducins directly activated Gs. While receptor-
specific ICL3 pepducins had properties attributable to Gs-biased signaling such as reduced 
β2AR endocytosis and desensitization, these molecules were not effective at attenuating 
carbachol-induced contraction in human precision-cut lung slices [36]. Nevertheless, given 
the ability of pepducins to bias Gs-signaling, efforts are underway to identify small 
molecules that would have a similar bias. Initial efforts should involve screening compounds 
using the β2AR as a target to identify Gs-biased agonists, Gs-biased positive allosteric 
modulators and arrestin-biased negative allosteric modulators.
While stimulation of Gs signaling serves as a primary strategy for treating asthma, Gq 
signaling is also an important target. However, while inhibiting human ASM contraction can 
serve as an effective means of treating asthma, one problem is that there are many Gq-
coupled receptors that are activated in asthma or COPD including the M3 muscarinic 
acetylcholine, cysteinyl leukotriene, H1 histamine, thromboxane, endothelin-A/B and others. 
To assess whether broad inhibition of Gq signaling is effective at attenuating ASM 
contraction, Carr et al. utilized several strategies to inhibit Gq including the Gαq specific 
inhibitor FR900359 (aka UBO-QIC) and a Gq-coupled receptor pepducin that appears to 
function as an antagonist [36]. FR900359 was confirmed as a selective Gq inhibitor which 
does not substantially effect Gs, Gi or G12/13 activity. Both the P4pal-10 pepducin and the 
small molecule FR900359 were effective at inhibiting Gq-mediated signaling and growth in 
primary HASM cells, while only FR900359 effectively inhibited agonist-promoted airway 
contraction in human precision cut lung slices [36]. In addition the pepducin P4pal-10, 
derived from the intracellular loop of the protease-activated receptor (PAR) 4, was 
determined to function as a broad-based Gq inhibitor in HEK293 and human ASM cells 
(Figure 3; data from Carr et al. [36].) P4pal-10 was shown to inhibit Gq coupling to 
receptors including PAR1, M3 muscarinic acetylcholine (M3 mAChR), and H1 histamine 
(H1R), whereas no direct effects on Gq or the ability to antagonize GPCRs coupled to Gs 
were observed. Consistent with its ability to inhibit M3 mAChR and histamine H1R 
coupling to Gq, p4Pal-10 inhibited ASM contraction induced by carbachol and histamine. 
These studies, using two approaches to inhibit Gq signaling, indicate that inhibition of Gq 
signaling at the receptor locus may be a feasible approach to treat several pathophysiological 
processes in airway disease.
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Figure 1. 
General concept of biased agonism. An unbiased agonist will induce balanced signaling by 
promoting coupling to G proteins and GRKs/ β-arrestins. This typically will promote G 
protein-dependent and β-arrestin-dependent signaling as well as GPCR desensitization, 
endocytosis and degradation. In contrast, a biased agonist will induce a receptor 
conformation that will enable selective activation of G protein — dependent or G protein-
independent (arrestin) signaling. In addition, for those GPCRs capable of coupling to 
multiple G proteins, biased ligands may preferentially promote GPCR coupling to a specific 
G protein. Accordingly, biased agonism can dramatically influence the functional 
consequences of receptor activation, and influence receptor desensitization.
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Figure 2. 
A proposed mechanism of action for pepducin effects on GPCR function. The lipidated 
nature of the peptides fosters pepducin incorporation into the outer leaflet of the 
plasmalemma. The fluidity of the pepducin to move within the plasma membrane can 
stabilize the GPCR conformation and/ or prevent G protein interaction to promote or inhibit 
intracellular signaling [1].
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Figure 3. 
Pepducins as inhibitors of GPCR-Gq signaling. Agonist-promoted calcium mobilization was 
monitored by Fura-2 AM fluorescence in agonist-stimulated HEK293 (PAR1-AP, ATP, 
Carbachol) and human ASM cells (Bradykinin, Histamine) pretreated for 1 min with 
indicated concentrations of P4pal-10. Data from Carr et al. Mol Pharmacol 2016; values are 
mean ± SD, n = 3.
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